Established in Beijing in 2015, Yuanxin Technology is a healthcare technology firm that zeroes in on the complete medical service cycle for patients. In October 2021, the company submitted its prospectus to the Hong Kong Stock Exchange and successfully cleared the listing hearing, yet it didn't move forward with the listing process. On April 22, 2026, Yuanxin Technology once more submitted its prospectus to the Hong Kong Stock Exchange, with the ambition of getting listed on the main board, and Huatai International acting as the sole sponsor.

Yuanxin Technology reported an annual revenue of 10.4 billion yuan, accompanied by a loss of 400 million yuan. It has secured the requisite licenses to offer insurance services within China. Since rolling out its insurance services in 2018, as of December 31, 2025, Yuanxin Technology has overseen the management of 247 million insurance policies, bringing benefits to roughly 4.8 million individuals. In addition, the company renders marketing services to 506 pharmaceutical companies and has forged partnerships with 537 hospitals, among which are over 220 Grade A Tertiary Hospitals.

In 2023, Yuanxin Technology unveiled the Yuanquan Patient Management Large Model and the Huizhi AI Large Model to bolster its digital prowess. Financial data reveals that Yuanxin Technology's revenue climbed from 9.737 billion yuan in 2023 to 10.377 billion yuan in 2025, accompanied by a substantial decrease in the adjusted net loss. What's more, the company achieved positive operating cash flow in both 2024 and 2025.